274 related articles for article (PubMed ID: 29472926)
41. The Lyme disease vaccine takes its toll.
Thomas V; Fikrig E
Vector Borne Zoonotic Dis; 2002; 2(4):217-22. PubMed ID: 12804162
[TBL] [Abstract][Full Text] [Related]
42. Demonstration of the ability of a canine Lyme vaccine to reduce the incidence of histological synovial lesions following experimentally-induced canine Lyme borreliosis.
Grosenbaugh DA; Rissi DR; Krimer PM
Vet Immunol Immunopathol; 2016 Nov; 180():29-33. PubMed ID: 27692092
[TBL] [Abstract][Full Text] [Related]
43. Reactogenicity and immunogenicity of a Lyme disease vaccine in children 2-5 years old.
Beran J; De Clercq N; Dieussaert I; Van Hoecke C
Clin Infect Dis; 2000 Dec; 31(6):1504-7. PubMed ID: 11096024
[TBL] [Abstract][Full Text] [Related]
44. Borreliacidal activity of sera from hamsters infected with the Lyme disease spirochete.
Lovrich SD; Callister SM; Schmitz JL; Alder JD; Schell RF
Infect Immun; 1991 Aug; 59(8):2522-8. PubMed ID: 1855973
[TBL] [Abstract][Full Text] [Related]
45. Structure of a transmission blocking antibody in complex with Outer surface protein A from the Lyme disease spirochete, Borreliella burgdorferi.
Rudolph MJ; Davis SA; Haque HME; Ejemel M; Cavacini LA; Vance DJ; Willsey GG; Piazza CL; Weis DD; Wang Y; Mantis NJ
Proteins; 2023 Nov; 91(11):1463-1470. PubMed ID: 37455569
[TBL] [Abstract][Full Text] [Related]
46. A luminescence-based assay for evaluating bactericidal antibody to Borrelia burgdorferi in vaccinated horses' serum.
Lee JJ; Hsieh CL; Widman J; Mingala C; Ardeza Villanueva M; Feng H; Divers T; Chang YF
Equine Vet J; 2019 Sep; 51(5):669-673. PubMed ID: 30648279
[TBL] [Abstract][Full Text] [Related]
47. A Borrelia burgdorferi Surface-Exposed Transmembrane Protein Lacking Detectable Immune Responses Supports Pathogen Persistence and Constitutes a Vaccine Target.
Kung F; Kaur S; Smith AA; Yang X; Wilder CN; Sharma K; Buyuktanir O; Pal U
J Infect Dis; 2016 Jun; 213(11):1786-95. PubMed ID: 26747708
[TBL] [Abstract][Full Text] [Related]
48. Identification of Borrelia burgdorferi outer surface proteins.
Brooks CS; Vuppala SR; Jett AM; Akins DR
Infect Immun; 2006 Jan; 74(1):296-304. PubMed ID: 16368984
[TBL] [Abstract][Full Text] [Related]
49. Borrelia burgdorferi binding of host complement regulator factor H is not required for efficient mammalian infection.
Woodman ME; Cooley AE; Miller JC; Lazarus JJ; Tucker K; Bykowski T; Botto M; Hellwage J; Wooten RM; Stevenson B
Infect Immun; 2007 Jun; 75(6):3131-9. PubMed ID: 17420242
[TBL] [Abstract][Full Text] [Related]
50. A mouse model for Borrelia burgdorferi infection: approach to a vaccine against Lyme disease.
Simon MM; Schaible UE; Wallich R; Kramer MD
Immunol Today; 1991 Jan; 12(1):11-6. PubMed ID: 2015043
[TBL] [Abstract][Full Text] [Related]
51. Enhancement of immune response towards non-lipidized Borrelia burgdorferi recombinant OspC antigen by binding onto the surface of metallochelating nanoliposomes with entrapped lipophilic derivatives of norAbuMDP.
Křupka M; Mašek J; Bartheldyová E; Turánek Knötigová P; Plocková J; Korvasová Z; Škrabalová M; Koudelka Š; Kulich P; Zachová K; Czerneková L; Strouhal O; Horynová M; Šebela M; Miller AD; Ledvina M; Raška M; Turánek J
J Control Release; 2012 Jun; 160(2):374-81. PubMed ID: 22387453
[TBL] [Abstract][Full Text] [Related]
52. DNA vaccines expressing a fusion product of outer surface proteins A and C from Borrelia burgdorferi induce protective antibodies suitable for prophylaxis but Not for resolution of Lyme disease.
Wallich R; Siebers A; Jahraus O; Brenner C; Stehle T; Simon MM
Infect Immun; 2001 Apr; 69(4):2130-6. PubMed ID: 11254567
[TBL] [Abstract][Full Text] [Related]
53. Coordinated expression of Borrelia burgdorferi complement regulator-acquiring surface proteins during the Lyme disease spirochete's mammal-tick infection cycle.
Bykowski T; Woodman ME; Cooley AE; Brissette CA; Brade V; Wallich R; Kraiczy P; Stevenson B
Infect Immun; 2007 Sep; 75(9):4227-36. PubMed ID: 17562769
[TBL] [Abstract][Full Text] [Related]
54. Outer Membrane Proteins BB0405 and BB0406 Are Immunogenic, but Only BB0405 Is Required for Borrelia burgdorferi Infection.
Shrestha B; Kenedy MR; Akins DR
Infect Immun; 2017 Feb; 85(2):. PubMed ID: 27920211
[TBL] [Abstract][Full Text] [Related]
55. Elucidating the Immune Evasion Mechanisms of
Walter L; Sürth V; Röttgerding F; Zipfel PF; Fritz-Wolf K; Kraiczy P
Front Immunol; 2019; 10():2722. PubMed ID: 31849943
[No Abstract] [Full Text] [Related]
56. Development of an OspC-based tetravalent, recombinant, chimeric vaccinogen that elicits bactericidal antibody against diverse Lyme disease spirochete strains.
Earnhart CG; Buckles EL; Marconi RT
Vaccine; 2007 Jan; 25(3):466-80. PubMed ID: 16996663
[TBL] [Abstract][Full Text] [Related]
57. A recombinant vaccine for Lyme disease.
Wallich R; Kramer MD; Simon MM
Behring Inst Mitt; 1994 Dec; (95):106-8. PubMed ID: 7755503
[TBL] [Abstract][Full Text] [Related]
58. Temporal pattern of Borrelia burgdorferi p21 expression in ticks and the mammalian host.
Das S; Barthold SW; Giles SS; Montgomery RR; Telford SR; Fikrig E
J Clin Invest; 1997 Mar; 99(5):987-95. PubMed ID: 9062357
[TBL] [Abstract][Full Text] [Related]
59. Borreliacidal OspC antibodies specific for a highly conserved epitope are immunodominant in human lyme disease and do not occur in mice or hamsters.
Lovrich SD; Jobe DA; Schell RF; Callister SM
Clin Diagn Lab Immunol; 2005 Jun; 12(6):746-51. PubMed ID: 15939749
[TBL] [Abstract][Full Text] [Related]
60. Conformational nature of the Borrelia burgdorferi decorin binding protein A epitopes that elicit protective antibodies.
Ulbrandt ND; Cassatt DR; Patel NK; Roberts WC; Bachy CM; Fazenbaker CA; Hanson MS
Infect Immun; 2001 Aug; 69(8):4799-807. PubMed ID: 11447153
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
